Ayala Pharmaceuticals Inc Ordinary Shares ADXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADXS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.14
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–1.49
- Bid/Ask
- $0.12 / $0.17
- Market Cap
- $51,112.74
- Volume/Avg
- 633 / 11,171
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.ayalapharma.com
Valuation
|
Metric
|
ADXS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.56 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADXS
|
|---|---|
Quick Ratio | 0.20 |
Current Ratio | 0.30 |
Interest Coverage | −2.30 |
Quick Ratio
ADXS
Profitability
|
Metric
|
ADXS
|
|---|---|
Return on Assets (Normalized) | −380.79% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ADXS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Wwhpznmgx | Wbwl | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tzjckprd | Jpvxy | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wgqcnrmpf | Vmkgwm | $118.7 Bil | |||
| Moderna Inc
MRNA
| Tgqbdwr | Fsldt | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xfcwwdtnb | Qznkgqz | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Zxlnnvtp | Dctnk | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Wxwcjwqy | Ynsqv | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yvlwtnhg | Lptxm | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jygjmqdvr | Bwl | $15.0 Bil | |||
| Incyte Corp
INCY
| Hbrmkgr | Chgcfwv | $13.5 Bil |